1 minute reading time (45 words)

FDA Approves New Treatment for Patients with Migraine

The U.S. Food and Drug Administration approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.  

Related Posts

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More